skip navigation
NIH Record  
Vol. LXVI, No. 5
  February 28, 2014
Langer Makes a Career of Doing the Impossible
‘End of AIDS’ Is Topic of LaMontagne Lecture, Mar. 13 in Lipsett
Berger To Discuss Senescence, Aging In Mahoney Lecture
NIAMS Coalition Comes Together for Outreach, Education
printer friendly version
NIH, Industry and Non-Profits Partner to Speed Validation of Disease Targets

NIH director Dr. Francis Collins unveils AMP at National Press Club on Feb. 4.
NIH director Dr. Francis Collins unveils AMP at National Press Club on Feb. 4.
NIH, 10 biopharmaceutical companies and several nonprofit organizations launched an unprecedented partnership on Feb. 4 to transform the current model for identifying and validating the most promising biological targets of disease for new diagnostics and drug development.

The Accelerating Medicines Partnership (AMP) aims to distinguish biological targets of disease most likely to respond to new therapies and characterize biological indicators of disease, known as biomarkers. Through the Foundation for the NIH, AMP partners will invest more than $230 million over 5 years in the first projects, which focus on Alzheimer’s disease, type 2 diabetes and the autoimmune disorders rheumatoid arthritis and systemic lupus erythematosus (lupus).

Neighborhoods Do Exert Influence
Fuchs Describes Importance of Niche in Stem Cell Biology

Dr. Elaine Fuchs
Dr. Elaine Fuchs
Dr. Elaine Fuchs has taken advantage of the abundance and regenerative capacity of hair and skin to do groundbreaking research on stem cells. To keep harmful microbes out, retain fluids and repair wounds, humans must constantly replenish their body surface, the epidermis. Hence the skin stem cells that achieve this practically announce their suitability for study.

In her Jan. 15 talk “Carving Out a Niche for Stem Cells” in Masur Auditorium, Fuchs, who is Rebecca C. Lancefield professor of the laboratory of mammalian cell biology and development and HHMI investigator at Rockefeller University, described work that has pointed lately in the direction of determining the cause of squamous cell carcinomas of the skin, head and neck, tackling one of the most common and life-threatening cancers world-wide.